Withdrawal of warfarin prior to a surgical procedure: Time to follow the guidelines?

Sergey E. Akopov, Shuichi Suzuki, Andre Fredieu, Stella Kidwell, Jeffrey L. Saver, Stanley N. Cohen

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Background and Objective: Patients with cardiogenic sources of embolism may be at increased risk of cerebral infarction when anticoagulation therapy is suspended for surgical procedures. The purpose of this study was to determine frequency of cardioembolic cerebral infarction during periprocedural warfarin withdrawal. Methods: Retrospective analysis of prospective cerebral infarction registry data from two tertiary medical centers. Results: Over a 12-month period, 14 cases of cardioembolic cerebral infarction occurring during the period of warfarin withdrawal for a medical procedure were observed, accounting for 7.1% of the 197 cardioembolic cerebral infarctions encountered. Across all patients, cerebral infarctions developed an average of 5.4 days after the last dose of warfarin (range 3-8). Among the 14 patients (8 males and 6 females) with warfarin cessation-related infarcts, age ranged from 54 to 91 years. Each had been on chronic anticoagulation with warfarin for more than 1 year. Retrospective analysis suggested that all these cerebral infarctions had been potentially preventable. In each case, either the planned procedure did not require discontinuation of warfarin or, when withdrawal was required, no bridging, parenteral anticoagulation was provided to lessen the risk during the warfarin-free period. Conclusion: Patients at high risk of cardioembolic cerebral infarction may benefit from more intensive management strategies to reduce cerebral infarction risk during periprocedural periods.

Original languageEnglish (US)
Pages (from-to)337-342
Number of pages6
JournalCerebrovascular Diseases
Volume19
Issue number5
DOIs
StatePublished - Apr 2005
Externally publishedYes

Fingerprint

Cerebral Infarction
Warfarin
Guidelines
Embolism
Registries

Keywords

  • Atrial fibrillation
  • Cardioembolic stroke
  • Cerebrovascular disease
  • Warfarin

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Withdrawal of warfarin prior to a surgical procedure : Time to follow the guidelines? / Akopov, Sergey E.; Suzuki, Shuichi; Fredieu, Andre; Kidwell, Stella; Saver, Jeffrey L.; Cohen, Stanley N.

In: Cerebrovascular Diseases, Vol. 19, No. 5, 04.2005, p. 337-342.

Research output: Contribution to journalArticle

Akopov, Sergey E. ; Suzuki, Shuichi ; Fredieu, Andre ; Kidwell, Stella ; Saver, Jeffrey L. ; Cohen, Stanley N. / Withdrawal of warfarin prior to a surgical procedure : Time to follow the guidelines?. In: Cerebrovascular Diseases. 2005 ; Vol. 19, No. 5. pp. 337-342.
@article{5849d57cf689493b8a12482d4b497322,
title = "Withdrawal of warfarin prior to a surgical procedure: Time to follow the guidelines?",
abstract = "Background and Objective: Patients with cardiogenic sources of embolism may be at increased risk of cerebral infarction when anticoagulation therapy is suspended for surgical procedures. The purpose of this study was to determine frequency of cardioembolic cerebral infarction during periprocedural warfarin withdrawal. Methods: Retrospective analysis of prospective cerebral infarction registry data from two tertiary medical centers. Results: Over a 12-month period, 14 cases of cardioembolic cerebral infarction occurring during the period of warfarin withdrawal for a medical procedure were observed, accounting for 7.1{\%} of the 197 cardioembolic cerebral infarctions encountered. Across all patients, cerebral infarctions developed an average of 5.4 days after the last dose of warfarin (range 3-8). Among the 14 patients (8 males and 6 females) with warfarin cessation-related infarcts, age ranged from 54 to 91 years. Each had been on chronic anticoagulation with warfarin for more than 1 year. Retrospective analysis suggested that all these cerebral infarctions had been potentially preventable. In each case, either the planned procedure did not require discontinuation of warfarin or, when withdrawal was required, no bridging, parenteral anticoagulation was provided to lessen the risk during the warfarin-free period. Conclusion: Patients at high risk of cardioembolic cerebral infarction may benefit from more intensive management strategies to reduce cerebral infarction risk during periprocedural periods.",
keywords = "Atrial fibrillation, Cardioembolic stroke, Cerebrovascular disease, Warfarin",
author = "Akopov, {Sergey E.} and Shuichi Suzuki and Andre Fredieu and Stella Kidwell and Saver, {Jeffrey L.} and Cohen, {Stanley N.}",
year = "2005",
month = "4",
doi = "10.1159/000085027",
language = "English (US)",
volume = "19",
pages = "337--342",
journal = "Cerebrovascular Diseases",
issn = "1015-9770",
publisher = "S. Karger AG",
number = "5",

}

TY - JOUR

T1 - Withdrawal of warfarin prior to a surgical procedure

T2 - Time to follow the guidelines?

AU - Akopov, Sergey E.

AU - Suzuki, Shuichi

AU - Fredieu, Andre

AU - Kidwell, Stella

AU - Saver, Jeffrey L.

AU - Cohen, Stanley N.

PY - 2005/4

Y1 - 2005/4

N2 - Background and Objective: Patients with cardiogenic sources of embolism may be at increased risk of cerebral infarction when anticoagulation therapy is suspended for surgical procedures. The purpose of this study was to determine frequency of cardioembolic cerebral infarction during periprocedural warfarin withdrawal. Methods: Retrospective analysis of prospective cerebral infarction registry data from two tertiary medical centers. Results: Over a 12-month period, 14 cases of cardioembolic cerebral infarction occurring during the period of warfarin withdrawal for a medical procedure were observed, accounting for 7.1% of the 197 cardioembolic cerebral infarctions encountered. Across all patients, cerebral infarctions developed an average of 5.4 days after the last dose of warfarin (range 3-8). Among the 14 patients (8 males and 6 females) with warfarin cessation-related infarcts, age ranged from 54 to 91 years. Each had been on chronic anticoagulation with warfarin for more than 1 year. Retrospective analysis suggested that all these cerebral infarctions had been potentially preventable. In each case, either the planned procedure did not require discontinuation of warfarin or, when withdrawal was required, no bridging, parenteral anticoagulation was provided to lessen the risk during the warfarin-free period. Conclusion: Patients at high risk of cardioembolic cerebral infarction may benefit from more intensive management strategies to reduce cerebral infarction risk during periprocedural periods.

AB - Background and Objective: Patients with cardiogenic sources of embolism may be at increased risk of cerebral infarction when anticoagulation therapy is suspended for surgical procedures. The purpose of this study was to determine frequency of cardioembolic cerebral infarction during periprocedural warfarin withdrawal. Methods: Retrospective analysis of prospective cerebral infarction registry data from two tertiary medical centers. Results: Over a 12-month period, 14 cases of cardioembolic cerebral infarction occurring during the period of warfarin withdrawal for a medical procedure were observed, accounting for 7.1% of the 197 cardioembolic cerebral infarctions encountered. Across all patients, cerebral infarctions developed an average of 5.4 days after the last dose of warfarin (range 3-8). Among the 14 patients (8 males and 6 females) with warfarin cessation-related infarcts, age ranged from 54 to 91 years. Each had been on chronic anticoagulation with warfarin for more than 1 year. Retrospective analysis suggested that all these cerebral infarctions had been potentially preventable. In each case, either the planned procedure did not require discontinuation of warfarin or, when withdrawal was required, no bridging, parenteral anticoagulation was provided to lessen the risk during the warfarin-free period. Conclusion: Patients at high risk of cardioembolic cerebral infarction may benefit from more intensive management strategies to reduce cerebral infarction risk during periprocedural periods.

KW - Atrial fibrillation

KW - Cardioembolic stroke

KW - Cerebrovascular disease

KW - Warfarin

UR - http://www.scopus.com/inward/record.url?scp=18644385945&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=18644385945&partnerID=8YFLogxK

U2 - 10.1159/000085027

DO - 10.1159/000085027

M3 - Article

C2 - 15818034

AN - SCOPUS:18644385945

VL - 19

SP - 337

EP - 342

JO - Cerebrovascular Diseases

JF - Cerebrovascular Diseases

SN - 1015-9770

IS - 5

ER -